Vaxcyte, Inc. Files Q1 2025 10-Q Report
Ticker: PCVX · Form: 10-Q · Filed: May 7, 2025 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: PCVX
TL;DR
Vaxcyte's Q1 2025 10-Q is in. Check financials & biz updates.
AI Summary
Vaxcyte, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial figures and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with a quarterly update on Vaxcyte's financial health and operational progress, crucial for understanding the company's trajectory in the biotechnology sector.
Risk Assessment
Risk Level: medium — Biotechnology companies like Vaxcyte face inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Players & Entities
- Vaxcyte, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250507 (date) — Filing date
- San Carlos, CA (location) — Company headquarters
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 7, 2025.
What is Vaxcyte, Inc.'s primary business sector?
Vaxcyte, Inc. operates in the Biological Products sector, specifically excluding diagnostic substances.
What was Vaxcyte's former company name?
Vaxcyte, Inc.'s former company name was SutroVax, Inc., with a name change effective July 24, 2015.
Where is Vaxcyte, Inc. headquartered?
Vaxcyte, Inc. is headquartered at 825 Industrial Road, Ste. 300, San Carlos, CA 94070.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Vaxcyte, Inc. (PCVX).